Home » Archive

Drug Development

Drug Development, News, Syndication, Xconomy »

What the World Needs Now Is (Probably Not) a Pill for Perfect Pitch

Posted by sandiegobiotech January 27th, 2014 .
No Comments

I remember seeing an episode of Desperate Housewives during the show’s first season called Running to Stand Still. In the episode, Lynette, working mom of many, takes her kid’s ADD medicine in order…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

San Diego Life Sciences Roundup: Orexigen, Avalon, GSK, and More

Posted by sandiegobiotech November 27th, 2013 .
No Comments

Here’s my pre-holiday wrap-up of San Diego’s life sciences news. Have a happy Thanksgiving! —San Diego’s Orexigen Therapeutics (NASDAQ: OREX) said it plans to resubmit its new drug application…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

Glaxo Setting Up San Diego Outpost to Oversee its Westward Expansion

Posted by sandiegobiotech November 25th, 2013 .
No Comments

The British multinational pharmaceutical giant GlaxoSmithKline (NYSE: GSK) is establishing an R&D outpost in San Diego to help manage its relationships with venture capital firms, and to prospect…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

San Diego Life Sciences Roundup: Isis, Neurocrine, MEI, and More

Posted by sandiegobiotech September 12th, 2013 .
No Comments

Isis Pharmaceuticals extended its reach in neurological drugs this week by signing its fourth collaboration agreement with Biogen Idec. We have that and the rest of San Diego’s life sciences news…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

La Jolla Institute Extends 25-Year Partnership with Japanese Pharma

Posted by sandiegobiotech July 30th, 2013 .
No Comments

[Corrected 8/01/13, 00:30 am. See below.] The La Jolla Institute for Allergy and Immunology says it has extended its industry-academic collaboration with the California-based subsidiary of Kyowa…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

After Raising $59M, aTyr Plans Physiocrines Proof-of-Concept Trials

Posted by sandiegobiotech July 28th, 2013 .
No Comments

San Diego’s aTyr Pharma says today it has closed on $59 million in a Series D financing to advance its development of a new class of protein-based drugs for treating rare immune diseases. The $59…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

Constructing Innovation Supply Chains for the Pharmaceutical Industry

Posted by sandiegobiotech June 26th, 2013 .
No Comments

Competition via innovation has been recognized as essential for mid- to long-term success and even survival of science-based corporations such as pharmaceutical and biotechnology companies. As such,…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

San Diego’s Receptos, Ambit Biosciences, Get Ready for IPO Debuts

Posted by sandiegobiotech May 6th, 2013 .
No Comments

[Corrected 5/6/13, 10:50 am. See below.] San Diego-based Receptos, a biotech developing new treatments for immune disorders, is among 13 IPOs expected to go public this week, according to Renaissance…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

Abide Therapeutics and Merck Unveil Diabetes Drug Collaboration

Posted by sandiegobiotech May 2nd, 2013 .
No Comments

Abide Therapeutics, a two-year-old San Diego biopharmaceutical firm pioneering new ways to identify and validate drug targets among the serine hydrolase “superfamily” of enzymes, says today it has…

[[Click headline to continue reading.]]

More...

Drug Development, News, Syndication, Xconomy »

Rare FDA Ruling Triggers Stampede for Acadia Pharmaceuticals

Posted by sandiegobiotech April 11th, 2013 .
No Comments

How often does the FDA tell a drug developer to dispense with a requisite, second late-stage trial—and to proceed with filing a new drug application? Shares of San Diego’s Acadia…

[[Click headline to continue reading.]]

More...